Mardi Dier serves as the Executive Vice President and Chief Financial Officer at Madrigal Pharmaceuticals, Inc., a position she has held since joining the company in 2018. With over 25 years of experience in financial management and strategic planning within the biopharmaceutical industry, Dier has been instrumental in guiding Madrigal through its growth phases. Before joining Madrigal, she held key financial leadership positions at several prominent companies, including Aventine Bioenergy and Human Genome Sciences, where she played a pivotal role in overseeing major financial operations and strategic initiatives. At Madrigal Pharmaceuticals, Dier's responsibilities encompass a broad range of financial activities, including financial planning, budgeting, and investor relations. Her strategic vision has been crucial in steering the company towards its goal of developing innovative treatments for non-alcoholic steatohepatitis (NASH). Under her leadership, Madrigal has successfully navigated the complex financial landscape of drug development, securing necessary funding and maintaining strong investor confidence. Dier's achievements at Madrigal include the successful management of the company's IPO and subsequent financings, which have been vital in advancing the company's clinical programs. Mardi Dier's career is marked by her ability to drive financial strategies that support long-term growth and stability. Her expertise in the biopharmaceutical sector, combined with her strategic acumen, makes her an invaluable asset to Madrigal Pharmaceuticals. As the company continues to progress towards bringing new treatments to market, Dier's role will remain central to its success, ensuring that the company remains financially robust and well-positioned for future opportunities.